Joshua Levine to Hypoglycemic Agents
This is a "connection" page, showing publications Joshua Levine has written about Hypoglycemic Agents.
Connection Strength
0.248
-
Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States. Curr Med Res Opin. 2022 Nov; 38(11):1785-1795.
Score: 0.164
-
Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies. Diabetes Obes Metab. 2023 04; 25(4):965-974.
Score: 0.043
-
Efficacy of tirzepatide 5, 10 and 15?mg versus semaglutide 2?mg in patients with type 2 diabetes: An adjusted indirect treatment comparison. Diabetes Obes Metab. 2022 09; 24(9):1861-1868.
Score: 0.041